4
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour stage
- Metastatic
- Combined Agent(s)
- Cisplatin
- Control Arm
- Cisplatin + gemcitabine
- Treatment Setting
- 1st line stage III or IV (non-squamous)
Primary Outcome(s)
- Primary Outcome(s)
- OS (non-inferiority)
- Form(s)
- Form 2c
Outcome Data
- OS Control
- 10.4 months
- OS Gain
- 1.4 months
- OS HR
- 0.81 (0.70-0.94)
- Toxicity Comment
- Less grade 3+ toxicity: neutropenia anaemia thrombocytopenia
Final Score (after adjustments)
- Preliminary non-curative score
- 4
- Final non-curative Score
- 4
ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression